Firm Characteristics and the Speed of FDA Approval
Author:
- 1 March 1997
- journal article
- Published by Wiley in Journal of Economics & Management Strategy
- Vol. 6 (1) , 377-401
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Substitution in Regulatory Agencies: FDA Enforcement AlternativesThe Journal of Law, Economics, and Organization, 1996
- Research and Development Costs for New Drugs by Therapeutic CategoryPharmacoEconomics, 1995
- Do Important Drugs Reach the Market Sooner?The RAND Journal of Economics, 1994
- Strategic Regulators and the Choice of Rulemaking Procedures: The Selection of Formal vs. Informal Rules in Regulating Hazardous WasteLaw and Contemporary Problems, 1994
- Cost of innovation in the pharmaceutical industryJournal of Health Economics, 1991
- Therapeutic Ratings and End‐of‐Phase II Conferences: Initiatives to Accelerate the Availability of Important New Drugs Kenneth I. Kaitin, PhDThe Journal of Clinical Pharmacology, 1991
- Control and Feedback in Economic Regulation: The Case of the NLRBAmerican Political Science Review, 1985
- Toward a More General Theory of RegulationThe Journal of Law and Economics, 1976
- Inflation and Environmental Concern: Structural Change in the Process of Public Utility Price RegulationThe Journal of Law and Economics, 1974
- The Theory of Economic RegulationThe Bell Journal of Economics and Management Science, 1971